Company news
MediciNova, Inc. news in 2022
MediciNova, Inc.'s news releases, calls and decks from 2022, newest first.
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
December 5, 2022
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
December 4, 2022
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
September 13, 2022
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
September 12, 2022
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
August 15, 2022
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
August 8, 2022
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
July 26, 2022
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
July 25, 2022
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
July 20, 2022
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
June 28, 2022
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
June 21, 2022
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
June 7, 2022
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
April 19, 2022
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
April 11, 2022
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
April 10, 2022
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
April 6, 2022
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
March 16, 2022
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
February 27, 2022
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
February 21, 2022
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
January 31, 2022
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
January 30, 2022
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
January 26, 2022
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe
January 25, 2022